nodes	percent_of_prediction	percent_of_DWPC	metapath
Terazosin—ABCB1—Mitomycin—urinary bladder cancer	0.188	0.506	CbGbCtD
Terazosin—ADRA1B—vas deferens—urinary bladder cancer	0.0959	0.471	CbGeAlD
Terazosin—ABCB1—Gemcitabine—urinary bladder cancer	0.0541	0.146	CbGbCtD
Terazosin—ABCB1—Cisplatin—urinary bladder cancer	0.0393	0.106	CbGbCtD
Terazosin—ABCB1—Etoposide—urinary bladder cancer	0.0386	0.104	CbGbCtD
Terazosin—ABCB1—Doxorubicin—urinary bladder cancer	0.0263	0.0709	CbGbCtD
Terazosin—ABCB1—Methotrexate—urinary bladder cancer	0.0255	0.0686	CbGbCtD
Terazosin—Prazosin—MT3—urinary bladder cancer	0.0172	1	CrCbGaD
Terazosin—KCNH6—prostate gland—urinary bladder cancer	0.0151	0.0742	CbGeAlD
Terazosin—KCNH6—renal system—urinary bladder cancer	0.0103	0.0506	CbGeAlD
Terazosin—ADRA1D—prostate gland—urinary bladder cancer	0.00838	0.0411	CbGeAlD
Terazosin—KCNH6—female reproductive system—urinary bladder cancer	0.00826	0.0405	CbGeAlD
Terazosin—ADRA1D—epithelium—urinary bladder cancer	0.00616	0.0302	CbGeAlD
Terazosin—ADRA1B—renal system—urinary bladder cancer	0.00584	0.0287	CbGeAlD
Terazosin—ADRA1D—urethra—urinary bladder cancer	0.00561	0.0275	CbGeAlD
Terazosin—ADRA1A—prostate gland—urinary bladder cancer	0.00481	0.0236	CbGeAlD
Terazosin—KCNH2—prostate gland—urinary bladder cancer	0.00465	0.0228	CbGeAlD
Terazosin—ADRA1D—female reproductive system—urinary bladder cancer	0.00457	0.0224	CbGeAlD
Terazosin—KCNH2—seminal vesicle—urinary bladder cancer	0.00393	0.0193	CbGeAlD
Terazosin—ADRA1A—epithelium—urinary bladder cancer	0.00354	0.0174	CbGeAlD
Terazosin—ADRA1A—renal system—urinary bladder cancer	0.00328	0.0161	CbGeAlD
Terazosin—KCNH2—renal system—urinary bladder cancer	0.00317	0.0155	CbGeAlD
Terazosin—KCNH2—urethra—urinary bladder cancer	0.00311	0.0153	CbGeAlD
Terazosin—KCNH2—female reproductive system—urinary bladder cancer	0.00254	0.0125	CbGeAlD
Terazosin—KCNH2—vagina—urinary bladder cancer	0.00229	0.0113	CbGeAlD
Terazosin—ABCB1—prostate gland—urinary bladder cancer	0.00204	0.01	CbGeAlD
Terazosin—ABCB1—seminal vesicle—urinary bladder cancer	0.00172	0.00846	CbGeAlD
Terazosin—ABCB1—epithelium—urinary bladder cancer	0.0015	0.00735	CbGeAlD
Terazosin—KCNH2—lymph node—urinary bladder cancer	0.00148	0.00728	CbGeAlD
Terazosin—ABCB1—renal system—urinary bladder cancer	0.00139	0.00682	CbGeAlD
Terazosin—ABCB1—urethra—urinary bladder cancer	0.00137	0.0067	CbGeAlD
Terazosin—ABCB1—female reproductive system—urinary bladder cancer	0.00111	0.00546	CbGeAlD
Terazosin—ABCB1—vagina—urinary bladder cancer	0.00101	0.00494	CbGeAlD
Terazosin—ABCB1—lymph node—urinary bladder cancer	0.000651	0.0032	CbGeAlD
Terazosin—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000523	0.00128	CcSEcCtD
Terazosin—Dysuria—Epirubicin—urinary bladder cancer	0.000521	0.00128	CcSEcCtD
Terazosin—Dizziness—Thiotepa—urinary bladder cancer	0.00052	0.00128	CcSEcCtD
Terazosin—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000516	0.00127	CcSEcCtD
Terazosin—Influenza—Doxorubicin—urinary bladder cancer	0.000515	0.00127	CcSEcCtD
Terazosin—Asthma—Doxorubicin—urinary bladder cancer	0.000515	0.00127	CcSEcCtD
Terazosin—Pollakiuria—Epirubicin—urinary bladder cancer	0.000514	0.00126	CcSEcCtD
Terazosin—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000514	0.00126	CcSEcCtD
Terazosin—Sweating—Methotrexate—urinary bladder cancer	0.000509	0.00125	CcSEcCtD
Terazosin—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000508	0.00125	CcSEcCtD
Terazosin—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000508	0.00125	CcSEcCtD
Terazosin—Paraesthesia—Etoposide—urinary bladder cancer	0.000507	0.00125	CcSEcCtD
Terazosin—Weight increased—Epirubicin—urinary bladder cancer	0.000507	0.00124	CcSEcCtD
Terazosin—Dyspnoea—Etoposide—urinary bladder cancer	0.000504	0.00124	CcSEcCtD
Terazosin—Somnolence—Etoposide—urinary bladder cancer	0.000502	0.00123	CcSEcCtD
Terazosin—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000502	0.00123	CcSEcCtD
Terazosin—Epistaxis—Methotrexate—urinary bladder cancer	0.0005	0.00123	CcSEcCtD
Terazosin—Vomiting—Thiotepa—urinary bladder cancer	0.0005	0.00123	CcSEcCtD
Terazosin—Rash—Thiotepa—urinary bladder cancer	0.000496	0.00122	CcSEcCtD
Terazosin—Bronchitis—Doxorubicin—urinary bladder cancer	0.000495	0.00122	CcSEcCtD
Terazosin—Dermatitis—Thiotepa—urinary bladder cancer	0.000495	0.00122	CcSEcCtD
Terazosin—Headache—Thiotepa—urinary bladder cancer	0.000493	0.00121	CcSEcCtD
Terazosin—Decreased appetite—Etoposide—urinary bladder cancer	0.000491	0.00121	CcSEcCtD
Terazosin—Body temperature increased—Cisplatin—urinary bladder cancer	0.000487	0.0012	CcSEcCtD
Terazosin—Fatigue—Etoposide—urinary bladder cancer	0.000487	0.0012	CcSEcCtD
Terazosin—Jaundice—Epirubicin—urinary bladder cancer	0.000484	0.00119	CcSEcCtD
Terazosin—Pain—Etoposide—urinary bladder cancer	0.000483	0.00119	CcSEcCtD
Terazosin—Constipation—Etoposide—urinary bladder cancer	0.000483	0.00119	CcSEcCtD
Terazosin—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000483	0.00119	CcSEcCtD
Terazosin—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000483	0.00119	CcSEcCtD
Terazosin—Dysuria—Doxorubicin—urinary bladder cancer	0.000482	0.00118	CcSEcCtD
Terazosin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000479	0.00118	CcSEcCtD
Terazosin—Sweating—Epirubicin—urinary bladder cancer	0.000476	0.00117	CcSEcCtD
Terazosin—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000476	0.00117	CcSEcCtD
Terazosin—Asthenia—Gemcitabine—urinary bladder cancer	0.000475	0.00117	CcSEcCtD
Terazosin—Pharyngitis—Methotrexate—urinary bladder cancer	0.000473	0.00116	CcSEcCtD
Terazosin—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00047	0.00115	CcSEcCtD
Terazosin—Weight increased—Doxorubicin—urinary bladder cancer	0.000469	0.00115	CcSEcCtD
Terazosin—Epistaxis—Epirubicin—urinary bladder cancer	0.000468	0.00115	CcSEcCtD
Terazosin—Pruritus—Gemcitabine—urinary bladder cancer	0.000468	0.00115	CcSEcCtD
Terazosin—Nausea—Thiotepa—urinary bladder cancer	0.000467	0.00115	CcSEcCtD
Terazosin—Sinusitis—Epirubicin—urinary bladder cancer	0.000466	0.00114	CcSEcCtD
Terazosin—Feeling abnormal—Etoposide—urinary bladder cancer	0.000465	0.00114	CcSEcCtD
Terazosin—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000462	0.00113	CcSEcCtD
Terazosin—Pruritus—Fluorouracil—urinary bladder cancer	0.00046	0.00113	CcSEcCtD
Terazosin—Visual impairment—Methotrexate—urinary bladder cancer	0.000459	0.00113	CcSEcCtD
Terazosin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000454	0.00112	CcSEcCtD
Terazosin—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000453	0.00111	CcSEcCtD
Terazosin—Jaundice—Doxorubicin—urinary bladder cancer	0.000448	0.0011	CcSEcCtD
Terazosin—Rhinitis—Epirubicin—urinary bladder cancer	0.000447	0.0011	CcSEcCtD
Terazosin—Abdominal pain—Etoposide—urinary bladder cancer	0.000446	0.0011	CcSEcCtD
Terazosin—Body temperature increased—Etoposide—urinary bladder cancer	0.000446	0.0011	CcSEcCtD
Terazosin—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000446	0.0011	CcSEcCtD
Terazosin—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000446	0.0011	CcSEcCtD
Terazosin—Eye disorder—Methotrexate—urinary bladder cancer	0.000445	0.00109	CcSEcCtD
Terazosin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000445	0.00109	CcSEcCtD
Terazosin—Tinnitus—Methotrexate—urinary bladder cancer	0.000444	0.00109	CcSEcCtD
Terazosin—Asthenia—Cisplatin—urinary bladder cancer	0.000442	0.00109	CcSEcCtD
Terazosin—Pharyngitis—Epirubicin—urinary bladder cancer	0.000442	0.00109	CcSEcCtD
Terazosin—Sweating—Doxorubicin—urinary bladder cancer	0.00044	0.00108	CcSEcCtD
Terazosin—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000439	0.00108	CcSEcCtD
Terazosin—Epistaxis—Doxorubicin—urinary bladder cancer	0.000433	0.00106	CcSEcCtD
Terazosin—Sinusitis—Doxorubicin—urinary bladder cancer	0.000431	0.00106	CcSEcCtD
Terazosin—Dizziness—Fluorouracil—urinary bladder cancer	0.00043	0.00106	CcSEcCtD
Terazosin—Visual impairment—Epirubicin—urinary bladder cancer	0.000429	0.00105	CcSEcCtD
Terazosin—Diarrhoea—Cisplatin—urinary bladder cancer	0.000422	0.00104	CcSEcCtD
Terazosin—Vomiting—Gemcitabine—urinary bladder cancer	0.000421	0.00103	CcSEcCtD
Terazosin—Rash—Gemcitabine—urinary bladder cancer	0.000417	0.00102	CcSEcCtD
Terazosin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000417	0.00102	CcSEcCtD
Terazosin—Eye disorder—Epirubicin—urinary bladder cancer	0.000416	0.00102	CcSEcCtD
Terazosin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000416	0.00102	CcSEcCtD
Terazosin—Tinnitus—Epirubicin—urinary bladder cancer	0.000415	0.00102	CcSEcCtD
Terazosin—Malnutrition—Methotrexate—urinary bladder cancer	0.000415	0.00102	CcSEcCtD
Terazosin—Headache—Gemcitabine—urinary bladder cancer	0.000414	0.00102	CcSEcCtD
Terazosin—Vomiting—Fluorouracil—urinary bladder cancer	0.000413	0.00102	CcSEcCtD
Terazosin—Rhinitis—Doxorubicin—urinary bladder cancer	0.000413	0.00102	CcSEcCtD
Terazosin—Rash—Fluorouracil—urinary bladder cancer	0.00041	0.00101	CcSEcCtD
Terazosin—Dermatitis—Fluorouracil—urinary bladder cancer	0.00041	0.00101	CcSEcCtD
Terazosin—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000409	0.00101	CcSEcCtD
Terazosin—Headache—Fluorouracil—urinary bladder cancer	0.000407	0.001	CcSEcCtD
Terazosin—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000406	0.000998	CcSEcCtD
Terazosin—Dysgeusia—Methotrexate—urinary bladder cancer	0.000406	0.000997	CcSEcCtD
Terazosin—Asthenia—Etoposide—urinary bladder cancer	0.000405	0.000995	CcSEcCtD
Terazosin—Back pain—Methotrexate—urinary bladder cancer	0.000401	0.000985	CcSEcCtD
Terazosin—Pruritus—Etoposide—urinary bladder cancer	0.0004	0.000981	CcSEcCtD
Terazosin—Arrhythmia—Epirubicin—urinary bladder cancer	0.000398	0.000978	CcSEcCtD
Terazosin—Visual impairment—Doxorubicin—urinary bladder cancer	0.000397	0.000976	CcSEcCtD
Terazosin—Nausea—Gemcitabine—urinary bladder cancer	0.000393	0.000965	CcSEcCtD
Terazosin—Vomiting—Cisplatin—urinary bladder cancer	0.000392	0.000963	CcSEcCtD
Terazosin—Vision blurred—Methotrexate—urinary bladder cancer	0.000391	0.000959	CcSEcCtD
Terazosin—Rash—Cisplatin—urinary bladder cancer	0.000389	0.000955	CcSEcCtD
Terazosin—Dermatitis—Cisplatin—urinary bladder cancer	0.000388	0.000954	CcSEcCtD
Terazosin—Malnutrition—Epirubicin—urinary bladder cancer	0.000388	0.000953	CcSEcCtD
Terazosin—Diarrhoea—Etoposide—urinary bladder cancer	0.000386	0.000949	CcSEcCtD
Terazosin—Nausea—Fluorouracil—urinary bladder cancer	0.000386	0.000949	CcSEcCtD
Terazosin—Eye disorder—Doxorubicin—urinary bladder cancer	0.000385	0.000946	CcSEcCtD
Terazosin—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000385	0.000945	CcSEcCtD
Terazosin—Tinnitus—Doxorubicin—urinary bladder cancer	0.000384	0.000944	CcSEcCtD
Terazosin—Flatulence—Epirubicin—urinary bladder cancer	0.000382	0.000939	CcSEcCtD
Terazosin—Tension—Epirubicin—urinary bladder cancer	0.000381	0.000935	CcSEcCtD
Terazosin—Dysgeusia—Epirubicin—urinary bladder cancer	0.00038	0.000933	CcSEcCtD
Terazosin—Nervousness—Epirubicin—urinary bladder cancer	0.000377	0.000925	CcSEcCtD
Terazosin—Back pain—Epirubicin—urinary bladder cancer	0.000375	0.000922	CcSEcCtD
Terazosin—Malaise—Methotrexate—urinary bladder cancer	0.000374	0.000918	CcSEcCtD
Terazosin—Dizziness—Etoposide—urinary bladder cancer	0.000373	0.000917	CcSEcCtD
Terazosin—Vertigo—Methotrexate—urinary bladder cancer	0.000372	0.000915	CcSEcCtD
Terazosin—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000368	0.000905	CcSEcCtD
Terazosin—Nausea—Cisplatin—urinary bladder cancer	0.000366	0.000899	CcSEcCtD
Terazosin—Vision blurred—Epirubicin—urinary bladder cancer	0.000366	0.000898	CcSEcCtD
Terazosin—Cough—Methotrexate—urinary bladder cancer	0.000362	0.000888	CcSEcCtD
Terazosin—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00036	0.000884	CcSEcCtD
Terazosin—Convulsion—Methotrexate—urinary bladder cancer	0.000359	0.000882	CcSEcCtD
Terazosin—Vomiting—Etoposide—urinary bladder cancer	0.000359	0.000882	CcSEcCtD
Terazosin—Malnutrition—Doxorubicin—urinary bladder cancer	0.000359	0.000882	CcSEcCtD
Terazosin—Rash—Etoposide—urinary bladder cancer	0.000356	0.000875	CcSEcCtD
Terazosin—Dermatitis—Etoposide—urinary bladder cancer	0.000356	0.000874	CcSEcCtD
Terazosin—Headache—Etoposide—urinary bladder cancer	0.000354	0.000869	CcSEcCtD
Terazosin—Flatulence—Doxorubicin—urinary bladder cancer	0.000354	0.000869	CcSEcCtD
Terazosin—Arthralgia—Methotrexate—urinary bladder cancer	0.000353	0.000867	CcSEcCtD
Terazosin—Myalgia—Methotrexate—urinary bladder cancer	0.000353	0.000867	CcSEcCtD
Terazosin—Chest pain—Methotrexate—urinary bladder cancer	0.000353	0.000867	CcSEcCtD
Terazosin—Tension—Doxorubicin—urinary bladder cancer	0.000352	0.000865	CcSEcCtD
Terazosin—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000351	0.000863	CcSEcCtD
Terazosin—Malaise—Epirubicin—urinary bladder cancer	0.00035	0.000859	CcSEcCtD
Terazosin—Discomfort—Methotrexate—urinary bladder cancer	0.000349	0.000856	CcSEcCtD
Terazosin—Nervousness—Doxorubicin—urinary bladder cancer	0.000349	0.000856	CcSEcCtD
Terazosin—Vertigo—Epirubicin—urinary bladder cancer	0.000349	0.000856	CcSEcCtD
Terazosin—Syncope—Epirubicin—urinary bladder cancer	0.000348	0.000854	CcSEcCtD
Terazosin—Back pain—Doxorubicin—urinary bladder cancer	0.000347	0.000853	CcSEcCtD
Terazosin—Palpitations—Epirubicin—urinary bladder cancer	0.000343	0.000842	CcSEcCtD
Terazosin—Confusional state—Methotrexate—urinary bladder cancer	0.000341	0.000838	CcSEcCtD
Terazosin—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000341	0.000837	CcSEcCtD
Terazosin—Cough—Epirubicin—urinary bladder cancer	0.000339	0.000831	CcSEcCtD
Terazosin—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000338	0.000831	CcSEcCtD
Terazosin—Vision blurred—Doxorubicin—urinary bladder cancer	0.000338	0.000831	CcSEcCtD
Terazosin—Convulsion—Epirubicin—urinary bladder cancer	0.000336	0.000825	CcSEcCtD
Terazosin—Nausea—Etoposide—urinary bladder cancer	0.000335	0.000824	CcSEcCtD
Terazosin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000333	0.000818	CcSEcCtD
Terazosin—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000331	0.000814	CcSEcCtD
Terazosin—Myalgia—Epirubicin—urinary bladder cancer	0.00033	0.000811	CcSEcCtD
Terazosin—Chest pain—Epirubicin—urinary bladder cancer	0.00033	0.000811	CcSEcCtD
Terazosin—Arthralgia—Epirubicin—urinary bladder cancer	0.00033	0.000811	CcSEcCtD
Terazosin—Anxiety—Epirubicin—urinary bladder cancer	0.000329	0.000808	CcSEcCtD
Terazosin—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000327	0.000803	CcSEcCtD
Terazosin—Discomfort—Epirubicin—urinary bladder cancer	0.000326	0.000801	CcSEcCtD
Terazosin—Malaise—Doxorubicin—urinary bladder cancer	0.000324	0.000795	CcSEcCtD
Terazosin—Dry mouth—Epirubicin—urinary bladder cancer	0.000323	0.000793	CcSEcCtD
Terazosin—Vertigo—Doxorubicin—urinary bladder cancer	0.000322	0.000792	CcSEcCtD
Terazosin—Anorexia—Methotrexate—urinary bladder cancer	0.000322	0.000792	CcSEcCtD
Terazosin—Syncope—Doxorubicin—urinary bladder cancer	0.000322	0.000791	CcSEcCtD
Terazosin—Confusional state—Epirubicin—urinary bladder cancer	0.000319	0.000784	CcSEcCtD
Terazosin—Palpitations—Doxorubicin—urinary bladder cancer	0.000317	0.000779	CcSEcCtD
Terazosin—Oedema—Epirubicin—urinary bladder cancer	0.000317	0.000778	CcSEcCtD
Terazosin—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000317	0.000778	CcSEcCtD
Terazosin—Hypotension—Methotrexate—urinary bladder cancer	0.000316	0.000776	CcSEcCtD
Terazosin—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000315	0.000775	CcSEcCtD
Terazosin—Cough—Doxorubicin—urinary bladder cancer	0.000313	0.000769	CcSEcCtD
Terazosin—Shock—Epirubicin—urinary bladder cancer	0.000311	0.000765	CcSEcCtD
Terazosin—Convulsion—Doxorubicin—urinary bladder cancer	0.000311	0.000764	CcSEcCtD
Terazosin—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00031	0.000761	CcSEcCtD
Terazosin—Tachycardia—Epirubicin—urinary bladder cancer	0.000309	0.000759	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000308	0.000757	CcSEcCtD
Terazosin—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000306	0.000752	CcSEcCtD
Terazosin—Insomnia—Methotrexate—urinary bladder cancer	0.000306	0.000752	CcSEcCtD
Terazosin—Myalgia—Doxorubicin—urinary bladder cancer	0.000306	0.000751	CcSEcCtD
Terazosin—Arthralgia—Doxorubicin—urinary bladder cancer	0.000306	0.000751	CcSEcCtD
Terazosin—Chest pain—Doxorubicin—urinary bladder cancer	0.000306	0.000751	CcSEcCtD
Terazosin—Anxiety—Doxorubicin—urinary bladder cancer	0.000305	0.000748	CcSEcCtD
Terazosin—Paraesthesia—Methotrexate—urinary bladder cancer	0.000304	0.000746	CcSEcCtD
Terazosin—Discomfort—Doxorubicin—urinary bladder cancer	0.000302	0.000742	CcSEcCtD
Terazosin—Anorexia—Epirubicin—urinary bladder cancer	0.000302	0.000741	CcSEcCtD
Terazosin—Dyspnoea—Methotrexate—urinary bladder cancer	0.000302	0.000741	CcSEcCtD
Terazosin—Somnolence—Methotrexate—urinary bladder cancer	0.000301	0.000739	CcSEcCtD
Terazosin—Dry mouth—Doxorubicin—urinary bladder cancer	0.000299	0.000734	CcSEcCtD
Terazosin—Dyspepsia—Methotrexate—urinary bladder cancer	0.000298	0.000731	CcSEcCtD
Terazosin—Hypotension—Epirubicin—urinary bladder cancer	0.000296	0.000727	CcSEcCtD
Terazosin—Confusional state—Doxorubicin—urinary bladder cancer	0.000295	0.000725	CcSEcCtD
Terazosin—Decreased appetite—Methotrexate—urinary bladder cancer	0.000294	0.000722	CcSEcCtD
Terazosin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000293	0.000719	CcSEcCtD
Terazosin—Oedema—Doxorubicin—urinary bladder cancer	0.000293	0.000719	CcSEcCtD
Terazosin—Fatigue—Methotrexate—urinary bladder cancer	0.000292	0.000716	CcSEcCtD
Terazosin—Pain—Methotrexate—urinary bladder cancer	0.000289	0.000711	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000288	0.000708	CcSEcCtD
Terazosin—Shock—Doxorubicin—urinary bladder cancer	0.000288	0.000708	CcSEcCtD
Terazosin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000287	0.000704	CcSEcCtD
Terazosin—Insomnia—Epirubicin—urinary bladder cancer	0.000286	0.000703	CcSEcCtD
Terazosin—Tachycardia—Doxorubicin—urinary bladder cancer	0.000286	0.000702	CcSEcCtD
Terazosin—Paraesthesia—Epirubicin—urinary bladder cancer	0.000284	0.000698	CcSEcCtD
Terazosin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000283	0.000696	CcSEcCtD
Terazosin—Dyspnoea—Epirubicin—urinary bladder cancer	0.000282	0.000693	CcSEcCtD
Terazosin—Somnolence—Epirubicin—urinary bladder cancer	0.000281	0.000691	CcSEcCtD
Terazosin—Anorexia—Doxorubicin—urinary bladder cancer	0.000279	0.000686	CcSEcCtD
Terazosin—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000279	0.000685	CcSEcCtD
Terazosin—Dyspepsia—Epirubicin—urinary bladder cancer	0.000279	0.000684	CcSEcCtD
Terazosin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000277	0.000679	CcSEcCtD
Terazosin—Decreased appetite—Epirubicin—urinary bladder cancer	0.000275	0.000676	CcSEcCtD
Terazosin—Hypotension—Doxorubicin—urinary bladder cancer	0.000274	0.000672	CcSEcCtD
Terazosin—Fatigue—Epirubicin—urinary bladder cancer	0.000273	0.00067	CcSEcCtD
Terazosin—Pain—Epirubicin—urinary bladder cancer	0.000271	0.000665	CcSEcCtD
Terazosin—Constipation—Epirubicin—urinary bladder cancer	0.000271	0.000665	CcSEcCtD
Terazosin—Abdominal pain—Methotrexate—urinary bladder cancer	0.000267	0.000657	CcSEcCtD
Terazosin—Body temperature increased—Methotrexate—urinary bladder cancer	0.000267	0.000657	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000267	0.000656	CcSEcCtD
Terazosin—Insomnia—Doxorubicin—urinary bladder cancer	0.000265	0.000651	CcSEcCtD
Terazosin—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000263	0.000646	CcSEcCtD
Terazosin—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000261	0.000641	CcSEcCtD
Terazosin—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000261	0.000641	CcSEcCtD
Terazosin—Somnolence—Doxorubicin—urinary bladder cancer	0.00026	0.00064	CcSEcCtD
Terazosin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000259	0.000636	CcSEcCtD
Terazosin—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000258	0.000633	CcSEcCtD
Terazosin—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000255	0.000625	CcSEcCtD
Terazosin—Fatigue—Doxorubicin—urinary bladder cancer	0.000253	0.00062	CcSEcCtD
Terazosin—Constipation—Doxorubicin—urinary bladder cancer	0.000251	0.000615	CcSEcCtD
Terazosin—Pain—Doxorubicin—urinary bladder cancer	0.000251	0.000615	CcSEcCtD
Terazosin—Abdominal pain—Epirubicin—urinary bladder cancer	0.00025	0.000615	CcSEcCtD
Terazosin—Body temperature increased—Epirubicin—urinary bladder cancer	0.00025	0.000615	CcSEcCtD
Terazosin—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000249	0.000612	CcSEcCtD
Terazosin—Asthenia—Methotrexate—urinary bladder cancer	0.000243	0.000596	CcSEcCtD
Terazosin—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000241	0.000593	CcSEcCtD
Terazosin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00024	0.000588	CcSEcCtD
Terazosin—Pruritus—Methotrexate—urinary bladder cancer	0.000239	0.000588	CcSEcCtD
Terazosin—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000233	0.000573	CcSEcCtD
Terazosin—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000232	0.000569	CcSEcCtD
Terazosin—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000232	0.000569	CcSEcCtD
Terazosin—Diarrhoea—Methotrexate—urinary bladder cancer	0.000231	0.000569	CcSEcCtD
Terazosin—Asthenia—Epirubicin—urinary bladder cancer	0.000227	0.000558	CcSEcCtD
Terazosin—Pruritus—Epirubicin—urinary bladder cancer	0.000224	0.00055	CcSEcCtD
Terazosin—Dizziness—Methotrexate—urinary bladder cancer	0.000224	0.000549	CcSEcCtD
Terazosin—Diarrhoea—Epirubicin—urinary bladder cancer	0.000217	0.000532	CcSEcCtD
Terazosin—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000216	0.00053	CcSEcCtD
Terazosin—Vomiting—Methotrexate—urinary bladder cancer	0.000215	0.000528	CcSEcCtD
Terazosin—Rash—Methotrexate—urinary bladder cancer	0.000213	0.000524	CcSEcCtD
Terazosin—Dermatitis—Methotrexate—urinary bladder cancer	0.000213	0.000523	CcSEcCtD
Terazosin—Headache—Methotrexate—urinary bladder cancer	0.000212	0.000521	CcSEcCtD
Terazosin—Asthenia—Doxorubicin—urinary bladder cancer	0.00021	0.000516	CcSEcCtD
Terazosin—Dizziness—Epirubicin—urinary bladder cancer	0.000209	0.000514	CcSEcCtD
Terazosin—Pruritus—Doxorubicin—urinary bladder cancer	0.000207	0.000509	CcSEcCtD
Terazosin—Vomiting—Epirubicin—urinary bladder cancer	0.000201	0.000494	CcSEcCtD
Terazosin—Nausea—Methotrexate—urinary bladder cancer	0.000201	0.000494	CcSEcCtD
Terazosin—Diarrhoea—Doxorubicin—urinary bladder cancer	0.0002	0.000492	CcSEcCtD
Terazosin—Rash—Epirubicin—urinary bladder cancer	0.0002	0.00049	CcSEcCtD
Terazosin—Dermatitis—Epirubicin—urinary bladder cancer	0.000199	0.00049	CcSEcCtD
Terazosin—Headache—Epirubicin—urinary bladder cancer	0.000198	0.000487	CcSEcCtD
Terazosin—Dizziness—Doxorubicin—urinary bladder cancer	0.000194	0.000476	CcSEcCtD
Terazosin—Nausea—Epirubicin—urinary bladder cancer	0.000188	0.000462	CcSEcCtD
Terazosin—Vomiting—Doxorubicin—urinary bladder cancer	0.000186	0.000457	CcSEcCtD
Terazosin—Rash—Doxorubicin—urinary bladder cancer	0.000185	0.000454	CcSEcCtD
Terazosin—Dermatitis—Doxorubicin—urinary bladder cancer	0.000185	0.000453	CcSEcCtD
Terazosin—Headache—Doxorubicin—urinary bladder cancer	0.000184	0.000451	CcSEcCtD
Terazosin—Nausea—Doxorubicin—urinary bladder cancer	0.000174	0.000427	CcSEcCtD
